Angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin receptor blockers (ARBs) are widely prescribed for the management of hypertension. ACE inhibitors (ACE-I) and, more recently, ARBs have an established track record of success in the treatment of congestive heart failure (CHF), proteinuric renal disease and most recently the hypertensive patient with a high cardiac-risk profile. The individual success of each of these drug classes has fuelled speculation that given together the overall effect of both would exceed that of either given alone. This premise, although biologically plausible, has yet to be proven in a convincing enough fashion to support the routine use of these two drug classes in combination. Additional clarifying studies are needed to establish whether specific patient subsets exist that might benefit from such combination therapy.
Introduction
Inhibition of the renin-angiotensin system (RAS) by administration of either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) reduces blood pressure (BP) to a similar extent in hypertensive patients. 1 Both ACE inhibitors (ACE-I) and ARBs delay the progressive deterioration in renal function, which underscores renal injury, particularly in patients with diabetic nephropathy. [2] [3] [4] The renoprotective effects of these drugs in part relates to their ability to reduce proteinuria. [5] [6] ACE-I also improve the prognosis of patients with a high risk of atherothrombotic cardiovascular events, not unlike the effects that have now been observed with ARBs. [7] [8] [9] Moreover, ACE-I and ARBs are both of proven benefit in conditions of left ventricular (LV) dysfunction. [10] [11] It was just a matter of time before ACE-I and ARBs were to be given together as combination therapy, in that emerging evidence suggested these agents to be complementary in their actions. Unfortunately, very few published studies exist, which might allow an assessment of the effects of combined ACE-I and ARB therapy. Of the available studies in hypertension, [12] [13] [14] [15] [16] [17] [18] proteinuric/nephropathic states, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] or CHF, [10] [11] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] the observed results have been inconsistent and poorly generalisable. The present review briefly summarises the basis for combined use of ACE-I and ARBs, and describes the results of clinical trials in which such a combination has been examined.
Theoretical basis for combining ACE inhibitors and angiotensin receptor blockers
The pharmacological actions of ACE-I and ARBs have been well characterised. The BP reduction and/or tissue protection derived from interrupting the RAS with either an ACE-I or an ARB are in large a measure of an extension of compound-specific pharmacokinetic/pharmacodynamic properties. [43] [44] Numerous factors influence the final response to these drug classes, including where inhibition occurs in the RAS, any compensatory changes in RAS activity that arise from such blockade, and any additional unique effects on non-RAS systems. 44 Administration of an ACE-I initially reduces both circulating and tissue concentrations of angiotensin II (Ang II) by blocking the enzymatic conversion of angiotensin I (Ang I) to Ang II via ACE. However, long-term treatment with an ACE-I is accompanied by a gradual return of circulating and tissue Ang II concentrations to pre-treatment levels, a phenomenon termed 'Ang II escape'. [45] [46] [47] [48] One suggested explanation for Ang II escape centres on the capacity of enzymes in human tissues, such as chymase, cathepsin G and CAGE (chymostatin-sensitive angiotensin-generating enzyme), which can form Ang II from a variety of peptide substrates. 49 Since this mode of Ang II generation is independent of ACE, it can proceed in an unbridled fashion, even in the presence of an ACE-I.
These alternative non-ACE-dependent pathways for production of Ang II can upregulate with chronic ACE inhibition, although the precise stimulus for this remains unclear. 50 In addition, ACE activity increases in diseased tissues, such as atheromatous lesions which have been subjected to angioplasty. 51 This traditional pathway for production of Ang II is incompletely suppressed even by high-dose ACE-I therapy. [51] [52] Despite strong evidence in support of the concept of Ang II escape in heart failure, escape from the BP-reducing effects of an ACE-I has yet to be described. 44, 53 If Ang II escape with ACE-I is ever to be of relevance to clinical practice, it will not be on the basis of loss of BP control, an easily measured and treated parameter; rather, it is likely to be as a consequence of 'suboptimal tissue protection'.
ACE is also known as kininase-II, which is largely in control of the proteolytic breakdown of bradykinin and similar small vasoactive peptides. Accordingly, ACE inhibition inhibits the breakdown of bradykinin to biologically inactive products. The resultant increase in bradykinin promotes release of the potent vasodilator, nitric oxide (NO), via activation of the endothelial-based B 2 -receptor. It is generally accepted that at least part of the vasodepressor response to ACE-I therapy is bradykinin-mediated. 54 Blockade of the Ang II AT 1 -receptor with an ARB does not affect bradykinin by the ACE degradative pathway, and this clearly differentiates ACE-I and ARBs pharmacologically. Alternatively, AT 2 -receptor stimulation, as a sequelae to ARB therapy, can increase renal interstitial fluid bradykinin concentrations. This process is potentiated by co-administration of an ACE-I. 55
Interpretative issues in combining ACE inhibitors and angiotensin receptor blockers
The basis for combining an ACE-I with an ARB is to achieve a therapeutic outcome better than that seen with either drug administered alone.The theoretical premise behind the combination of these two drug classes is plausible to a degree, but there are pitfalls that may be encountered if only superficial analyses of response are performed.
First, there are a number of ACE-I and ARBs marketed worldwide. Drugs within each of these classes have differing durations of action; thus, the combination of a short-acting ACE-I, such as enalapril, with a long-acting ARB, such as telmisartan, can achieve a more prolonged response. This can be mistaken for an additive response when in reality it is little more than a mixing of drugs with different half-lives for a sustained effect on BP.
Secondly, the time of day that drugs in these classes are administered should be considered in assessing a response. Split dosing of these drug classes, with one being given in the morning and the other given in the evening, may be considered more effective than giving both drugs simultaneously. In reality, this approach may differ little from split-dosing a single agent.
Thirdly, the sequence in which these medications are given may determine the final BP response.The fall in BP that occurs with an ACE-I relates to both a reduction in Ang II levels and a variable increase in bradykinin effect. If the latter is an important contributor to BP reduction, then the order in which an ACE-I is added may dictate the pattern of response. Theoretically, adding the ARB after the ACE-I may have little effect on bradykinin levels, whereas beginning treatment with an ARB and then adding the ACE-I may uncover an additional vasodepressor response attributable to bradykinin.
Finally, the time course of response to the combination of an ACE-I and an ARB is mechanistically relevant. For example, if the combination of these drugs results in a drop in BP shortly after beginning combination therapy, a direct pharmacokinetic/pharmacodynamic ACE-I effect is likely. If a response occurs, but it takes several weeks, then the possibility exists that the combination of these drug classes encouraged earlier vascular remodel-ling more than if either drug had been given alone. The most relevant question that remains, when the combination of an ACE-I with an ARB results in a positive response, is whether the same would have occurred with simple dose titration of one or the other of the medications.Thus, exploring the dose-response curves of each component of this combination is a necessary exercise before considering the combination of these drug classes.
Clinical trial considerations Hypertension
The efficacy of both ACE-I and ARBs as antihypertensive agents is well established. 1, 44 In head-tohead comparisons, ACE-I and ARBs reduce BP comparably. 1 In contradistinction to the wealth of information on monotherapy with these drugs, there is sparingly little information about the efficacy of combined ACE-I and ARB therapy. [12] [13] [14] [15] [16] [17] [18] 33 Moreover, the trials currently published cannot be generalised, since in many instances they have studied only a small number of patients and many times have employed study designs with inherent limitations. For example, in one clinical trial, 20 patients received benazepril monotherapy for six weeks. If average awake ambulatory diastolic BPs remained >85 mmHg, subjects were randomised to receive either valsartan, 80 mg/day, or matching placebo in a blinded manner for five weeks, while continuing to receive background benazepril.The patients then crossed over to the alternative regimen for a second five-week period. Valsartan added to benazepril reduced BP by 6.5+12.6/ 4.5+8.0 mmHg (systolic/diastolic) over placebo for average awake ambulatory BP. Nocturnal systolic and diastolic BPs were similarly reduced (7.1+9.4/5.6+6.5). 16 In a larger, eight-week, open-label experience trial, the efficacy of the ARB, candesartan cilexetil, in a dose range of 16-32 mg was evaluated in 473 patients receiving ACE-I monotherapy. 15 The incremental reduction in BP with the addition of candesartan to an ACE-I was 15.3/10.0 mmHg. At first glance, this would appear to be a significant response. However, it is important to recognise that these studies were not placebo-controlled. A placebo effect could have easily contributed to the observed incremental response, by virtue of 'expectation bias'. Furthermore, these studies employed a variety of ACE-I given over a wide range of doses.The nature of this study precluded identifying the background ACE-I and their doses; thus, in these studies it is possible that background therapy with an ACE-I was not maximised before the addition of candesartan. African-Americans had a clinically important, but somewhat reduced BP response when candesartan was added to an ACE-I, although neither the exact number of African-American patients nor their response was reported. 15 Finally, there were 127 patients with isolated systolic hypertension in this clinical experience trial. They experienced a 13.4/4.3 mmHg drop in BP when candesartan was added to monotherapy. 15 There appears to be no basis for the use of an ACE-I in combination with an ARB in the Stage I or II hypertensive; most patients with BPs below 160/100 are likely to achieve goal BP with monotherapy or with a RAS antagonist plus a diuretic. Existing studies also fail to resolve the question of whether these drug classes should be routinely combined in the management of the complex hypertensive. 17 Additional studies are needed to determine whether there are subgroups of hypertensive patients that are uniquely responsive to the combination of an ACE-I and an ARB.
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One study, which will definitively answer many of the questions surrounding the use of combination ACE-I and ARB therapy, is the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study. This is a double-blind, parallel-group study involving 23,400 patients in 40 countries over a 5.5-year period. It will compare three treatment arms: (1) telmisartan (80 mg), (2) ramipril (10 mg), and (3) telmisartan (80 mg) plus ramipril (10 mg) in patients >55 years of age with a history of (1) coronary artery disease, (2) stroke, (3) peripheral vascular disease, or (4) diabetes mellitus with endorgan damage (microalbuminuria, ankle-brachial index <0.8, or LV hypertrophy). Patients with CHF will be excluded in this trial.
In a parallel study, patients unable to tolerate an ACE-I will be randomised to receive 80 mg of telmisartan or placebo (the Telmisartan Randomized AssessmeNt Study in ACE-I iNtolerant Patients with Cardiovascular Disease [TRAN-SCEND]).The primary endpoint for both trials is a composite of cardiovascular death, myocardial infarction (MI), stroke, and hospitalisation for heart failure. Secondary endpoints will investigate reductions in the development of diabetes mellitus, nephropathy, dementia, and atrial fibrillation. The population of the ONTARGET trial is at 3-fold greater risk than those in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), so between 4,000 and 5,000 primary endpoints are anticipated. 56 Both the ONTARGET and TRANSCEND trials are expected to be completed in 2007.
Congestive heart failure
The rationale for combination therapy with an ACE-I and an ARB in CHF is stronger than that for their combined use in hypertension. CHF is a disease state characterised by significant activation of the RAS, particularly in the later stages of the disease. Ang II escape is a not infrequent occurrence in the ACE-I-treated CHF patient. 45, 50, 57 Consequently, high-dose ACE-I therapy or combined ACE-I and ARB therapy has been advocated, in part because of the necessity to reduce either the generation or the effects of Ang II escape as completely as possible.
Results of several short-term trials, all with small numbers of patients and a number of them in patients with mild heart failure, have consistently shown that combined therapy with an ACE-I and an ARB additively decreases BP, improves ventricular remodelling parameters, increases oxygen consumption during exercise, and reduces plasma aldosterone and norepinephrine concentrations. 9, [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] These favourable effects on surrogate haemodynamic and neurohumoral parameters of CHF occur without apparent loss of drug regimen tolerability or increased adverse effects. Haemodynamic, neurohumoral and symptomatic improvement, however, do not necessarily equate with long-term survival.
Few data are currently available to evaluate the effect of combined therapy on heart failure-related mortality. 11 In the recently concluded Valsartan Heart Failure Trial (Val-HeFT), valsartan was compared with placebo on top of background ACE-I therapy in a cohort of 5,010 patients with New York Heart Association Class II-IV CHF (primarily Class II-III). 11 In both treatment arms, 93% of subjects were receiving ACE-I. After randomisation, valsartan was commenced at a dose of 40 mg b.d. and titrated to 160 mg b.d. The two primary outcome measures were all-cause mortality or a combined endpoint (all-cause mortality, which included sudden cardiac death with resuscitation, hospitalisation for heart failure, and worsening heart failure requiring inotropic or vasodilating agents). Compared with placebo, valsartan reduced the combined mortality/morbidity endpoint by 13.3%, and hospitalisation for heart failure by 27.5%, although all-cause mortality was not significantly reduced. 11 Practice guidelines in CHF management have not yet been updated to outline when, and in whom, an ARB should be added to an ACE-I. Such guidelines must ultimately consider the sequence of drugs to be added, given the expanding role of low-dose β-blocker therapy in CHF management. Thus, because no significant improvement was seen in Val-HeFT when valsartan was given to patients receiving both an ACE-I and a β-blocker, ARB therapy may become third-line therapy in CHF management unless a CHF patient is completely intolerant of ACE-I, in which case an ARB can be substituted for the ACE-I. If there is evidence of partial intolerance to an ACE-I at the early stage of dose titration -such as a precipitous decline in renal function or an excessive drop in BP -the addition of an ARB to a reduced dose of an ACE-I may succeed where dose titration alone has failed.
Two trials designed to evaluate the effects of combined ACE-I and ARB therapy in the postmyocardial infarction setting and in CHF are currently in the finishing stages. [58] [59] The first of these, the Valsartan in Acute Myocardial Infarction trial (VALIANT), is a multicentre, double-blind, randomised, active-controlled, parallel-group study, comparing the efficacy and safety of long-term treatment with valsartan, captopril, and their combination in high-risk patients after MI. 58 The second of these trials is a programme designed to investigate the clinical usefulness of the ARB, candesartan cilexetil, in a broad spectrum of patients with symptomatic heart failure (Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity [CHARM]). Specifically, the CHARM programme consists of three independent, parallel, placebo-controlled studies in patients with a LV ejection fraction (LVEF) of <40%, who are either ACE-I treated (combination therapy arm), or ACE-I intolerant, or patients with a LVEF ≥40 who have not previously received ACE-I. 59
Renal disease
The combination of an ACE-I and an ARB has been occasionally used in progressive renal disease, particularly for an antiproteinuric effect beyond that obtained with a single agent. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Insight into the potential mechanism(s) of the antiproteinuric effect with combination therapy can be gained from several recent studies. 20,60-61 Agarwal et al. have observed increased urinary levels of transforming growth factor β1 (TGFβ 1 ) in proteinuric patients with renal failure, despite maximal ACE inhibition (lisinopril 40 mg/day).The elevated levels of TGFβ 1 declined by 38% after one month of add-on therapy with losartan (50 mg/day). 20 Komine et al. have also shown that renal Ang II production is incompletely suppressed with the ACE-I, captopril, and that addition of the ARB, losartan, more completely suppresses production of Ang II. 60 This synergistic effect on Ang II may have important implications in long-term renoprotection. Finally, Delles et al. have shown that one week of treatment with the combination of enalapril (10 mg) and eprosartan (300 mg), (these doses representing half the usual dose of each drug), increased renal plasma flow by a NO-dependent mechanism. 61 The effect of combination therapy on protein excretion has been probed in a number of studies. For example, in an early study of normotensive patients with biopsy-documented immunoglobulin A nephropathy and non-nephrotic proteinuria, the combination of losartan with an ACE-I produced an average 73% greater reduction in proteinuria than either agent alone (ACE-I 38% and losartan 30%). In this study, no further reduction in proteinuria was observed by doubling the dose of either the ACE-I or of losartan. The observed change could not be explained by either a decline in systemic BP or by a fall in glomerular filtration rate and developed within four weeks of beginning combination therapy. 24 Recently, the randomised Candesartan and Lisinopril Microalbuminuria (CALM) study, which evaluated the effect of combining the ARB, candesartan, and the ACE-I, lisinopril, on microalbuminuria in 199 Type 2 diabetic patients, yielded similar observations.Twelve weeks of combination therapy was begun after 12 weeks of monotherapy with either candesartan or lisinopril, each given at onehalf the usual maximal dose. 23 In this study, the reduction in the urinary albumin: creatinine ratio with the combination of candesartan (16 mg/day) and lisinopril (20 mg/day) was significantly greater (50% decrease) than that observed with either agent alone (24 and 39% decrease with candesartan and lisinopril, respectively). As is often the case with combination therapy, BP values were lower than those obtained with either agent alone, which makes interpretation of the findings difficult. After 24 weeks of therapy, diastolic BP was reduced to a greater degree with combination therapy (-16.3 mmHg) than with either candesartan (-10.4 mmHg) or lisinopril (-10.7 mmHg) alone. 23 The importance of BP reduction in the additive antiproteinuric effects of combination therapy cannot be overemphasised. [21] [22] [23] 25 The relationship between BP and the antiproteinuric effect of combination therapy may not be detected if only officebased readings are used, as these have a high degree of intrinsic variability.A recent study by Russo et al. noted no relationship between office measurements of trough BP and the antiproteinuric effect of combination therapy with enalapril and losartan. However, there was a significantly high correlation between mean ambulatory BPs and the degree to which urinary protein excretion fell. 25 Additional studies will be required to determine whether longterm cardiovascular and renal outcome measures are more favourably impacted with combination therapy. Moreover, the optimal dose relationship, as well as the specific drug make-up, of an ACE-I and ARB combination remains to be determined.
Conclusions
ACE-I and ARBs are proven effective and well-tolerated antihypertensive agents. Moreover, these compounds have an established track record for effectiveness in the treatment of CHF, renal disease and/or proteinuric nephropathies. Although inconclusive, the results of a limited number of studies support the notion that additive antihypertensive, cardioprotective, and antiproteinuric effects may occasionally be obtained when ACE-I and ARBs are combined. More studies, though, are needed to confirm these preliminary observations, and to identify those subsets of patients who might derive greatest benefit from this combination approach. In particular, the question of whether maximal dose titration of either an ACE-I or an ARB would duplicate the clinical successes seen with combination therapy needs to be clarified.
